What Does Recombinetics Inc. Do?

Total employees75
HeadquartersSt. Paul
Founded2008

Recombinetics Inc. is a leading biotechnology company specializing in the development and application of precision gene-editing technologies. Their primary focus is on improving animal health, welfare, and productivity in agriculture (via subsidiary Acceligen) and developing gene-edited animal models for biomedical research and human therapeutic applications (via subsidiary Makana). They leverage advanced genetic tools like TALENs and CRISPR/Cas9 to create animals with desirable traits, such as disease resistance, enhanced productivity, and reduced environmental impact, as well as human-compatible organs for transplantation.

Where Is Recombinetics Inc.'s Headquarters?

HQ Function

The St. Paul headquarters serves as the central hub for Recombinetics' strategic leadership, core research and development activities, intellectual property management, business development, and administrative operations.

Notable Features:

Likely equipped with state-of-the-art laboratories for molecular biology, genetics, and embryology, along with bioinformatics capabilities. Its location provides proximity to the University of Minnesota and other research institutions.

Work Culture:

The work culture at Recombinetics is characterized by scientific innovation, collaboration, and a strong ethical focus. Employees are typically driven by the potential of gene editing to solve significant global challenges in food production and human health.

HQ Significance:

The headquarters' location in Minnesota allows Recombinetics to tap into a rich ecosystem of agricultural expertise, veterinary science, and biomedical talent, fostering collaborations and innovation.

Values Reflected in HQ: The headquarters reflects values of innovation, scientific excellence, ethical responsibility, and a commitment to advancing biotechnology for societal benefit.

Location:

Recombinetics Inc. establishes its global presence primarily through its subsidiaries (Acceligen for agriculture, Makana for human therapeutics), strategic partnerships, collaborations with international research institutions, and licensing of its gene-editing technologies. They target key agricultural markets worldwide and engage with the global biomedical community to advance their human health initiatives.

Street Address:

1295 Northland Dr, Suite 250

City:

St. Paul

State/Province:

Minnesota

Country:

USA

Where Else Does Recombinetics Inc. Operate Around the World?

Cordoba, Argentina

Address: Specific address not publicly listed, operates via Acceligen (subsidiary)

To implement and commercialize precision breeding technologies in South American livestock markets, adapting solutions to local agricultural needs and regulatory environments.

Mount Horeb, Wisconsin, USA

Address: Specific address related to Makana Therapeutics (subsidiary)

To advance the science and application of xenotransplantation, providing a dedicated facility for raising and studying genetically engineered pigs for organ transplantation into humans.

Buying Intent Signals for Recombinetics Inc.

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Recombinetics Inc.? Meet the Executive Team

As of April 2025, Recombinetics Inc.' leadership includes:

Mark Walton - Chief Executive Officer
Mitchell Abrahamsen - Executive Vice President & Chief Scientific Officer
Perry Hackett - Chief Scientific Advisor & Founder
Bobbie Kocon - Chief Financial Officer

Who's Investing in Recombinetics Inc.?

Recombinetics Inc. has been backed by several prominent investors over the years, including:

Open Prairie Rural Opportunities Fund
Ziegler Link-Age Longevity Fund
Medvec International
Makana PAG Holdings (related to Makana Therapeutics acquisition)
Various private equity and individual investors

What Leadership Changes Has Recombinetics Inc. Seen Recently?

Hire0
Exits0

Based on publicly available information, there have been no major, widely reported C-suite executive hires or exits at Recombinetics Inc. in the last 12 months. The core leadership team appears to have remained stable.

What Technology (Tech Stack) Is Used byRecombinetics Inc.?

Discover the tools Recombinetics Inc. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Recombinetics Inc. Email Formats and Examples

Recombinetics Inc. likely utilizes common corporate email formats. The most probable format is the first initial followed by the last name, or first name followed by last name, at their domain.

[first_initial][last]@recombinetics.com

Format

mwalton@recombinetics.com

Example

80%

Success rate

What's the Latest News About Recombinetics Inc.?

FDA • May 17, 2024

Recombinetics Inc. (via subsidiary Acceligen) receives FDA low-risk determination for marketing products from genome-edited beef cattle

The FDA announced a low-risk determination for marketing products, including food, from two genome-edited beef cattle and their offspring after determining the product is safe to eat. These PRLR-SLICK cattle, developed by Recombinetics' subsidiary Acceligen, are engineered to have slick coats, helping them better withstand hot weather, which can improve animal welfare and productivity....more

Recombinetics Press Release / Business Wire • September 14, 2023

Recombinetics Acquires Makana Therapeutics, Pioneer in Xenotransplantation

Recombinetics announced its acquisition of Makana Therapeutics, Inc., a company focused on developing genetically engineered pigs with organs suitable for human transplantation. This acquisition significantly expands Recombinetics' capabilities in the biomedical field....more

Successful Farming • March 21, 2022

Gene-edited pigs resistant to PRRS virus move closer to market

Recombinetics' subsidiary, Acceligen, has developed pigs genetically edited for resistance to Porcine Reproductive and Respiratory Syndrome (PRRS), a costly disease in the swine industry. The company is advancing towards commercialization....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Recombinetics Inc., are just a search away.